In January 2015, the FDA approved a bioengineered recombinant human PTH(1–84) [rhPTH(1–84)], as an adjunct to calcium and vitamin D therapy for the management of refractory hypoparathyroidism[6]. Here, PTH is linked to hypoparathyroidism.